RSCM
Rock Springs Capital Management Portfolio holdings
AUM
$1.6B
This Quarter Return
+8.38%
1 Year Return
+25.98%
3 Year Return
+194.74%
5 Year Return
+336.76%
10 Year Return
+2,199.29%
AUM
$1.6B
AUM Growth
+$1.6B
(-8.2%)
Cap. Flow
-$238M
Cap. Flow
% of AUM
-14.81%
Top 10 Holdings %
Top 10 Hldgs %
36.09%
Holding
105
New
9
Increased
32
Reduced
29
Closed
12
Top Buys
| 1 |
Agios Pharmaceuticals
AGIO
|
$21.5M |
| 2 |
CAI
Caris Life Sciences, Inc. Common Stock
CAI
|
$21.2M |
| 3 |
OMDA
Omada Health, Inc. Common Stock
OMDA
|
$16.8M |
| 4 |
SPDR S&P Biotech ETF
XBI
|
$12.6M |
| 5 |
Arcellx
ACLX
|
$12.3M |
Top Sells
| 1 |
BPMC
Blueprint Medicines
BPMC
|
$105M |
| 2 |
Nuvalent
NUVL
|
$25.5M |
| 3 |
Neurocrine Biosciences
NBIX
|
$23.9M |
| 4 |
Legend Biotech
LEGN
|
$17.4M |
| 5 |
UnitedHealth
UNH
|
$15.6M |
Sector Composition
| 1 | Healthcare | 98.9% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
BPMC
26
DELISTED
Blueprint Medicines
BPMC
| $23.8M | 1.48% |
185,500
-822,069
| -82% | -$105M |
|
27
Structure Therapeutics
GPCR
$1.11B
| $23.6M | 1.47% |
1,135,879
+2,900
| +0.3% | +$60.1K |
|
28
Tenet Healthcare
THC
$16.3B
| $22.9M | 1.43% |
130,000
| – | – |
|
|
CAI
29
Caris Life Sciences, Inc. Common Stock
CAI
$10.8B
| $21.2M | 1.32% |
+793,651
| New | +$21.2M |
|
30
Kymera Therapeutics
KYMR
$2.95B
| $19.7M | 1.22% |
450,374
-344,063
| -43% | -$15M |
|
|
OMDA
31
Omada Health, Inc. Common Stock
OMDA
$1.36B
| $16.8M | 1.05% |
+919,951
| New | +$16.8M |
|
32
Celldex Therapeutics
CLDX
$1.47B
| $16.5M | 1.03% |
812,653
| – | – |
|
33
Azenta
AZTA
$1.4B
| $16.3M | 1.02% |
530,400
+55,400
| +12% | +$1.71M |
|
34
Acadia Healthcare
ACHC
$2.12B
| $15.8M | 0.98% |
696,000
+14,900
| +2% | +$338K |
|
|
35
UnitedHealth
UNH
$281B
| $15.8M | 0.98% |
50,500
-50,000
| -50% | -$15.6M |
|
36
Tarsus Pharmaceuticals
TARS
$2.47B
| $15.1M | 0.94% |
373,750
+19,374
| +5% | +$785K |
|
37
Summit Therapeutics
SMMT
$17.6B
| $15.1M | 0.94% |
710,000
-285,000
| -29% | -$6.06M |
|
38
Agilon Health
AGL
$530M
| $15.1M | 0.94% |
6,550,400
-399,600
| -6% | -$919K |
|
39
Oscar Health
OSCR
$4.31B
| $15M | 0.94% |
700,000
-350,000
| -33% | -$7.5M |
|
40
Vera Therapeutics
VERA
$1.38B
| $14.5M | 0.91% |
617,396
+96,600
| +19% | +$2.28M |
|
41
Enliven Therapeutics
ELVN
$1.2B
| $14.1M | 0.88% |
701,408
+235,537
| +51% | +$4.72M |
|
42
Inspire Medical Systems
INSP
$2.77B
| $14M | 0.87% |
107,500
+8,250
| +8% | +$1.07M |
|
43
Soleno Therapeutics
SLNO
$3.6B
| $12.9M | 0.81% |
154,528
+30,433
| +25% | +$2.55M |
|
44
Compass Therapeutics
CMPX
$483M
| $12.9M | 0.8% |
4,962,955
| – | – |
|
|
45
SPDR S&P Biotech ETF
XBI
$5.07B
| $12.6M | 0.78% |
+151,750
| New | +$12.6M |
|
|
46
Arcellx
ACLX
$3.85B
| $12.3M | 0.76% |
+186,314
| New | +$12.3M |
|
|
MREO
47
Mereo BioPharma
MREO
$272M
| $12.1M | 0.75% |
4,465,292
-2,218,955
| -33% | -$6.01M |
|
48
Danaher
DHR
$147B
| $11.7M | 0.73% |
59,000
+200
| +0.3% | +$39.5K |
|
49
Amicus Therapeutics
FOLD
$2.34B
| $11.2M | 0.7% |
1,960,334
+50,972
| +3% | +$292K |
|
50
West Pharmaceutical
WST
$17.8B
| $11.2M | 0.7% |
51,030
-9,220
| -15% | -$2.02M |
|